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Foreword 
The long history of drug regulation, with its considerable achievements, has been marked by 
the persistence of one seemingly intractable paradox. The nature of the work of regulatory 
bodies means that they are continually entrusted with data given to them in confidence by 
pharmaceutical companies to make their assessments. Much of this material is unprotected 
by patent, so has to remain confidential to prevent leaks to competitors. One consequence of 
this situation has however often been a marked reluctance to grant other parties full access 
to regulatory proceedings; while the regulators have frequent close contact with industrial 
applicants, representatives of the public, in whose interests regulation exists, are commonly 
excluded from the process. That in turn leads many people, not only cynics, to regard 
regulation as primarily a process serving the needs and interests of the pharmaceutical 
industry. 
It is to the credit of the regulatory process in the European Union that it has in recent years 
tried to involve patient and consumer groups in some aspects of drug policy and approval. 
Experience seems to show that this can be achieved without endangering any other valid 
interest. But the procedures have to be well defined and respected, and the consumer 
groups involved must be financially independent and truly impartial. With some years of 
accumulated experience it is now possible to assess whether that ideal has indeed been 
achieved.  In the study presented here, Health Action International Europe has taken a 
uniquely close look at experience to date, particularly as regards the independence of the 
groups concerned; its findings will be important in determining the future pattern of public 
involvement in drug regulation.  
 
Dr. Graham Dukes, University of Oslo     
Dr. Andrew Herxheimer, Cochrane Collaboration 
   
Abstract  
Background 
The transparency criteria adopted by the European Medicines Agency require eligible patient 
and consumer organisations to disclose the names and contributions of their public and 
private revenue sources. Despite various transparency initiatives, the exact funding sources 
of, and amounts received by, eligible organisations remain unclear. This article examines 
how many patient and consumer organisations eligible to work with the Agency (n=23) 
received corporate sponsorship between 2006 and 2008 and how much. The article also 
reports how many organisations met the Agency‟s criteria on financial disclosure. 
Methods 
Financial data were retrieved from organisations‟ and pharmaceutical companies‟ websites in 
January and February 2010, as well as through direct requests for the information placed in 
March 2010. A method for estimating sponsorship in the absence of reported contributions 
was developed and applied uniformly. 
Results 
Fifteen of the twenty-three eligible organisations received financial sponsorship from 
corporate sources whilst seven received funding entirely from other sources. We failed to 
retrieve any financial data or revenue sources for one of the 23 organisations. The annual 
average corporate contribution per sponsored organisation rose from €185,500 in 2006, to 
€282,090 in 2007, to €321,230 in 2008. These amounts correspond to 47%, 51% and 57% of 
organisational average annual revenue, respectively. Fewer than half of the 23 organisations 
met the Agency‟s financial reporting guidelines.  
Conclusions 
This study indicates low compliance with the guidelines which EMA introduced in 2005 to 
ensure the financial transparency of the organisations working with it. Levels of corporate 
sponsorship differ greatly between those organisations that receive no financial support and 
others who rely upon it heavily. The lack of a uniform and detailed reporting system hinders 
complete public disclosure of the nature, and extent of, corporate sponsorship of these 
organisations.  
This study focuses on the issue of corporate sponsorship of patient and consumer 
organisations active at the EMA. However, these organisations represent only a selection of 
non-governmental organisations (NGOs) and other stakeholders active in the area of health 
and pharmaceutical policy in Europe. Thus, further research is called for on financial 
transparency, and the nature of corporate sponsorship and conflicts of interests of civil 
society representatives in European health policy making.  
 1 
Introduction 
Patient organisations have established themselves as a valuable source of information, 
services and support for those living with a disease and their carers. They can stimulate 
additional research in their disease area, promote public awareness for their condition and 
needs, and call for changes on behalf of patients.i The broader public is also affected by 
pharmaceutical policies and so consumer groups act as representatives for all those who on 
occasion or continuously, need medicinal treatment for a disease or condition.  
The growing trend for corporate financing of patient and/or consumer groups raises 
questions about their independence and the interests they represent in health and medicines 
policy fora.ii Pharmaceutical, bio-tech and medical device companies sponsor patient 
organisations in a variety of ways, ranging from direct financing to various forms of in-kind 
sponsorship.iii Despite overlapping objectives on some issues, the goals of groups 
representing medicines and device manufacturers can conflict with the aims of patients and 
consumers.iv For example, a manufacturer generally strives to obtain and expand market 
share for its products as quickly as possible to maximise returns. On the other hand, patients 
may or may not benefit, depending on the product characteristics, its cost, the range of 
existing treatments, and the new product‟s relative therapeutic value. For these reasons and 
others, a donor-recipient relationship forged between pharmaceutical companies and patient 
organisations could lead to conflicts of interest, or could unduly threaten the groups‟ 
independence.
1  
Patient organisations are increasingly involved as political stakeholders at the European 
Commission and related agencies. The European Medicines Agency (EMA) established a 
Patients‟ and Consumers‟ working group in 2005, which became a Working Party (PWCP) in 
2006. The PCWP makes recommendations to the Agency and its Management Board in 
matters that interest patients and consumers, including product information, transparency 
and dissemination of information, pharmacovigilance, and how patient organisations interact 
with the EMA Scientific Committees.v  
In 2005, the EMA developed clear guidelines (Criteria to be fulfilled by Patients’ and 
Consumers’ Organisations involved in EMEA Activitiesvi) requiring financial transparency 
from patient and consumer organisations that are eligible to work with the Agency. The 
Agency specifically asks for financial data to be disclosed in a format that includes the names 
of income sources and their corresponding financial contributions relative to the 
organisation‟s operating budget. The guidelines document does not include a monitoring 
procedure, concrete timelines for adherence, nor does it state the potential consequences of 
non-compliance. 
 2 
Despite various initiatives promoting financial transparency, the exact funding sources and 
amounts received by some eligible patient and consumer organisations remain unclear. 
Furthermore, little research has been done on the sources of funding of EMA‟s patient and 
consumer experts. This article examines the disclosure practices of eligible organisations. 
The article quantifies the annual corporate sponsorship that the patient and consumer groups 
active at the EMA have received in 2006, 2007 and 2008. It addresses the following 
questions: 
1. How many of the patient and consumer organisations that are eligible to work with the 
EMA have received corporate sponsorship?  
2. How much corporate sponsorship has each eligible organisation received? 
3. How many eligible organisations disclose corporate sponsorship in line with EMA 




On 1 August 2009 twenty-three patient and consumer organisations (hereafter called 




Conflict of Interest- A situation in which a person or organisation has a private or personal 
interest sufficient to appear to influence the objective exercise of his/her/its official duties.viii 
Declining sponsorship- Organisations were considered to have declined corporate 
sponsorship when their policy on financial support stated corporate or private company 
donations were not accepted and their website identified no corporate donors as financial 
contributors. 
Receiving sponsorship- This refers to financial contributions (i.e. restricted or unrestricted 
contributions for core/operational work, events, projects, education grants or research 
initiatives) and/or other types of contributions from corporate sources, such as payment of 
conference attendance and related travel costs for patient organisation representatives or 
honoraria.
 iii  
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In-kind contributions to the organisation‟s annual income from corporate or other sources 
were excluded from this study.1 
Sponsorship was identified in two ways:  
1) if the patient or consumer group reported revenue from a corporate source; 
2) if the company reported having provided a contribution to the patient or consumer group.  
 
Corporate sources were defined to include the following types of businesses and 
organisations:  
 Companies that produce healthcare-related products or services, including 
pharmaceuticals or medical devices; 
 Company-owned foundations, or foundations and associations established by a 
single company; 
 Industry associations representing medical, drug or device companies. 
The above enterprises and associations pursue economic objectives that could conflict with 
the aims of any patient and/or consumer organisation they sponsor, and have, therefore, 
been included in this study. 
We excluded non-profit foundations that received some health-sector corporate revenues if 
this was only a part of overall revenue. While these foundations are also private entities, their 
objectives are, in general, not in competition with those of patient and consumer groups. 
Foundations established by a single pharmaceutical company were included in the survey. 
Data sources 
Data for the years 2006, 2007, and 2008 were extracted from electronic sources between 
January 20 and February 7, 2010.  Average annual currency exchange rates were calculated 
from Oanda.com. 
Step 1: All financial data were first extracted from organisations‟ financial reports, annual 
reports, websites and other publications. When relevant documents could not be found, a 
Google search term was used: {patient or consumer organisation name} + annual report OR 
financial report OR finances OR sponsors OR donations + {year}. Only the first 20 results 
                                                 
1
 Although it is important to declare in-kind contributions as they can constitute corporate sponsorship, 
such contributions were excluded from this comparative study. In-kind contributions are assigned a 
self-determined value that can bias objective comparisons between organisational revenues. This 
includes, for example, corporate-sponsored administrative support or the economic value assigned to 
volunteer hours worked. 
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were investigated for efficiency, and in order to apply a systematic approach regardless of 
how many Google „hits‟ appeared per organisation.  
Step 2: The European Federation of Pharmaceutical Industry Associations (EFPIA) adopted 
a Code of Practice on Relationships between Pharmaceutical Industry and Patients 
Organisations in 2008.ix Under this self-regulatory code, all EFPIA member companies are 
requested to publish the names of the patient organisations they support.x EFPIA hosts a list 
of their 31 members that voluntarily declare patient group sponsorship and provides links to 
their websites at http://www.efpia.eu/content/default.asp?PageID=603. 
The 31 EFPIA members‟ websites were searched for financial data to supplement the 
information found on patient and consumer organisations‟ websites. If data could not be 
found on company websites, we used the Google search term: {company name} + {patient 
organisation name} OR patient organisation OR patient group + {year} 
The first 20 results were investigated. When a company‟s reported donation exceeded the 
contribution specified by the organisation, the difference was added to the amount reported 
by the organisation. 
Step 3: Finally, if sponsorship for at least one of the three years could not be accurately 
calculated from the data collected in the previous two steps, financial data in the EMA format 
was requested directly from organisations by e-mail during March 2010. This final step 
served as a validation tool for sponsorship estimates. 
Methods used to estimate sponsorship 
On occasion companies referred to their position or level on a donor hierarchy. For example, 
a company might be described as a Platinum Sponsor of the organisation. The term Platinum 
Sponsor was usually defined by the organisation as corresponding to a specific contribution, 
for example, €40000 in one case. 
In another case, the amount of the donation was known for only one of the Corporate 
Partners. An average Corporate Partner contribution was calculated based on the previous 
two years, both of which had a similar number of Corporate Partners and a comparable value 
of their total donations. The average Corporate Partner contribution was attributed to the 
remaining Corporate Partners for the year in question.  
If the information reported by patient groups did not distinguish between public and corporate 
donations, we used an estimation method. We investigated funding for projects that had 
corporate sponsorship, identified by company logos or acknowledgements published on 
project materials. It was assumed that each company donated an equal amount towards the 
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total, unless otherwise specified on the company website. Corporate sponsorship was 
calculated by aggregating the estimated company contributions for each project.  
Sometimes patient groups‟ annual financial reports did not identify project-specific income, 
but project-related expenses were clearly marked. In these cases, project expenses were 
assumed to be equal to the funds raised to execute the work. This allowed us to estimate the 
project-specific corporate sponsorship by assuming that each company donated an equal 
amount towards the total raised (see above).   
In all cases when detailed data on donations were not provided for at least one of the three 
years, we first asked the organisations to provide the data, and only used the estimation 
procedures described above when the data were not available.  
Methods used to estimate income 
The annual revenue was extracted from organisations‟ financial reports. In some cases, 
revenue was not reported.  
In the absence of reported revenue, we checked if the organisation was sponsored by a 
pharmaceutical company that specified its contribution in currency and as a percentage of 
the organisation‟s annual revenue. 
The following formula was used to estimate the organisational revenue: 
          [Company X contribution in euros (or converted to euros) * 100]           ]           
Company X contribution as a percentage of Organisation Y‟s annual revenue 
Results  
Fifteen of the twenty-three eligible organisations received financial sponsorship from 
corporate sources whilst seven received funding entirely from other sources. We failed to 
retrieve any financial data or revenue sources for one of the 23 organisations. 
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Table 1 - Corporate sponsorship of organisations eligible to work with the EMA  
  2006 2007 2008 
Group Name 


















European AIDS Treatment Group 




 € 650,39 90% € 642,20 83% 
International Alliance of Patients' 









European Organisation for Rare 
Diseases (EURORDIS) 
€ 347,00 25% € 451,00 20% € 492,00 25% 
European Patients' Forum (EPF) € 342,50 99% € 495,00 ^ 105% ^ € 458,50 78% 
European Parkinson's Disease 
Association (EPDA) 
€ 154,02 35% € 218,27 37% € 330,23 34% 
International Diabetes Federation  
Europe (IDF) 





European Federation of Neurological 
Associations (EFNA) 
€ 122,35 72% € 88,88 45% € 281,95 91% 
Alzheimer Europe (AE) € 183,18 24% € 221,41 25% € 248,69 26% 
European Multiple Sclerosis Platforms 
(EMSP) 
€ 213,30 48% € 216,12 33% € 242,34 32% 
International Patient Organisation for 
Primary Immunodeficiencies (IPOPI) 
€ 122,09 51% € 164,80 66% € 215,38 88% 
European Cancer Patient Coalition 













Myeloma Euronet (ME) € 133,60 99% € 190,94 94% € 170,17 79% 
European Genetic Alliances' Network 
(EGAN) 
€ 23,38 34% € 1,00 4% € 37,00 32% 
European Heart Network (EHN) € 0,79 0% € 0,00 0% € 0,00 0% 
AVERAGE € 185,50  47% # € 282,09  51% * € 321,23 * 57% * 
                                                 
 This is an estimate based on relevant but incomplete information from the organisation‟s website and 
donor company websites. 
^ This calculation is based on self-reported values; however, the amounts in the Acknowledgement of 
financial support section of the organisation’s annual report are not clearly reflected in the Profit and 
loss account section. Thus, the support reported from corporate sponsors exceeded the total income. 
 Average was calculated based on reported sponsorship values for the year indicated (n=14) 
 Average was calculated based on reported sponsorship values for the year indicated (n=13)  
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Table 2 - Organisations eligible to work with the EMA that did not receive sponsorship 
or where limited financial information was retrievable 
 
Did not receive corporate sponsorship in 2006, 2007 and 2008 
European Consumers' Organisation (BEUC) 
European Myeloma Platform (EMP) 
European Older People's Platform (AGE) 
European Public Health Alliance (EPHA) 
Health Action International Europe (HAI-E) 
Insulin Dependent Diabetes Trust (IDDT) 
International Confederation of Childhood Cancer Parents Organisations (ICCCPO) 
No financial information available for the years 2006, 2007 and 2008 
Rett Syndrome Europe (RSE) 
Received unspecified corporate sponsorship during 2006, 2007 or 2008 
European Heart Network (EHN)
2 
Thalassaemia International Federation (TIF) 
 
Organisations that received sponsorship 
Table 1 and Table 2 identify the 15 corporate-funded organisations. Of those sponsored, the 
level of corporate sponsorship ranged from 0.2% to 99.0% of their annual income. 
 
The annual average corporate contribution per sponsored organisation rose from €185,500 
in 2006, to €282,090 in 2007, to €321,230 in 2008. These amounts correspond to 47%, 51% 
and 57% of organisational average annual revenue, respectively. 
 
One organisation self-reported that it was funded exclusively by their members, who were 
identified as other patient- and disease-related organisations, and/or the European 
Commission, and therefore, (it was interpreted) that they did not accept sponsorship. 
However, a pharmaceutical company reported contributing honorariums to this patient group. 
 
Organisations that received no sponsorship 
Seven of the 23 eligible organisations received no corporate sponsorship, with four of the 
seven explicitly stating that they declined commercial funding. Table 2 lists the organisations 
that did not receive sponsorship and those where limited information was retrievable.  
                                                 
2
 Honorarium of unspecified amount in 2008 
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One organisation stated that its only two funding sources were an EU operating grant and 
member contributions. Two of the other organisations clearly state that they do not accept 
“funding from commercial entities” or “any financial assistance or sponsorship from 
pharmaceutical companies”. Although the fourth group‟s funding declaration is less specific, 
the secretariat clarified that their organisation “does not accept support, whether direct or 
indirect, from economic actors”. 
One organisation maintains a restricted funding policy, in which project- or event-related 
costs can be sponsored while operating costs cannot be financed by companies. However, 
their annual financial reports showed clearly that the organisation received no corporate 
sponsorship for a project, event or other restricted activity between 2006 and 2008.  
The Articles of Confederation of another organisation identify “national and international 
private entities” as viable income sources. A Sanofi-Aventis-sponsored project benefiting 
members was acknowledged in their annual report. However, in the context this research, 
this group was deemed not to receive sponsorship because their financial records do not 
identify any private donors and the direct recipients of Sanofi-Aventis support are unclear.  
One organisation lacks an identifiable funding policy, although its annual reports indicate that 
“most of our expenses in the year [year] were directly financed by our partner organisations, 
[...] members organisations or by individual members.” Its formal policy on corporate funding 
was unclear. 
Compliance with EMA transparency criteria 
Six organisations presented their financial data in the EMA format, for at least one of the 
three years studied. In some cases, the EMA format was adopted after we asked the 
organisation to direct us to these data, or provide us with them (methods step 3).3  
Nine additional organisations specified donors by name and their corresponding contribution, 
but did not express the donation as a percent of their total income. The financial records for 
two of these organisations were hosted on the UK Charity Commission website.xi  
                                                 
3
 Research steps 1 and 2 showed that HAI had not reported its revenue as a percentage of annual 
organisational income. The missing information was requested from HAI‟s Financial Director and HAI‟s 
public records have since been updated to comply with the EMA criteria. All other organisations 
contacted in research step 3 have had the same opportunity to update their financial data. 
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Discussion  
This research has found that 65% (n=15) of the 23 organisations working with the Agency 
received corporate sponsorship between 2006 to 2008, whilst 35% (n=7) did not. Only six of 
the 23 eligible organisations were found to meet the EMA‟s financial transparency criteria for 
at least one of the years examined. No financial data was located for one of the 23 
organisations. 
These results illustrate the lack of patient and consumer group compliance with the EMA 
criteria as well as the limited application of the guidelines. In addition, there is no indication 
that the EMA enforces or upholds the „public availability‟ requirement. The guidelines were 
introduced in 2005, but by March 2010, we were still unable to locate the income sources for 
20 of the 23 eligible groups reported online. Despite persistent non-reporting, all the 
organisations were invited to participate in the EMA annual meeting with eligible groups in 
December 2009.xii  
The importance of disclosure  
European patient and consumer organisations can voluntarily disclose their sources of 
revenue on their websites, but no common definition or format has been unanimously 
adopted. Disclosure of all sponsorship sources, its intended purpose, its value and the 
proportion of organisational revenue that it represents, is important because it provides a 
qualitative and quantitative evidence base from which to assess potential conflicts of interest. 
In general, patient groups‟ websites give insufficient information about corporate donors to 
assess whether their interests might conflict with those of their pharmaceutical and other 
corporate funders.
 iii  Although the European Commission introduced the voluntary „Register 
of Interest Representatives‟ in June 2008,xiii only five of the 22 organisations eligible to work 
with the Agency had registered by September 2009.xiv A significant majority of these groups 
conduct advocacy campaigns aimed at the EU Institutions on behalf of the patients and 
individuals they represent.4  
Unclear EMA financial reporting guidelines  
The EMA guidelines do not clearly define financial contribution, and therefore various 
differing definitions have been used in financial reporting. As a result, in some cases “other” 
donation types, such as honoraria and travel costs, were not reported as financial 
                                                 
4
 Nineteen of the 23 organisations sampled state that their mission includes the goal to raise 
awareness among  and/or to influence EU Institutions and Agencies. Source: EMA Working with 
Patients and Consumers – Eligible Organisations Accessed at: 
http://www.ema.europa.eu/Patients/organisations.htm on 31 March 2010. 
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contributions. Without clear definitions, discrepancies can arise and comparisons between 
organisations are difficult. These omissions also hinder assessment of possible conflicts of 
interest.  
Organisations used up to six different reporting formats in their reports. Reporting organised 
as combined contributions from unspecified donors was the most difficult to deconstruct. 
Financial links to corporate sponsors are obscured when public and private incomes are 
reported together as one contribution. In these circumstances, it is almost impossible to 
calculate or estimate the real value of sponsorship from the organisations‟ records alone. Full 
disclosure cannot be achieved without a uniform definition and format for financial reporting. 
The guidelines do not stipulate a reporting deadline or cycle, and some organisations have, 
as a result, not yet met the requirements established in 2005. Without a clear reporting 
timeline, an enforced monitoring procedure, and tangible consequences for non-compliance, 
the EMA guidelines for patient and consumer groups cannot secure the transparency of 
stakeholders. 
Alternative funding sources  
The EMA transparency guidelines apply to both public and private sources of funding. While 
this study only focuses on disclosure practices of corporate sources, financial support from 
public sources should also be disclosed.  
Besides corporate sponsorship, organisations sampled in this study relied partially or entirely 
on fees from member associations, foundation grant schemes, and funding programmes 
from national governments and European institutions. Some of these funding bodies have 
eligibility criteria that include a threshold on corporate co-financing. The Executive Agency for 
Health and Consumers (EAHC), which awarded 2009 or 2010 operating grants to six of the 
organisations sampled, considers applicant organisations receiving more than 20% of their 
funding from the private sector or other conflicting interest for their functioning to be ineligible 
to receive financial assistance.xv  
Absence of a uniform reporting system 
Despite the involvement of patients and consumers in pharmaceutical policy under both DG 
SANCO and DG Industry, there is neither a cohesive financial disclosure system nor detailed 
criteria for the participation of civil society organisations for pharmaceutical policy.   
The EAHC, under the competence of DG SANCO, employs a 20% threshold for corporate 
funding, determined following the submission of annual financial disclosure reports. This 
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threshold is enforced and organisations receiving more than 20% are ineligible to receive 
operating grants from EAHC.  
The European Union Health Policy Forum (EU HPF) is a multi-stakeholder platform hosted 
by DG SANCO that aims to contribute to and advise on the development, implementation 
and evaluation of EU health-related policies and actions.xvi The EU HPF adopted a series of 
Guiding Principles with regard to Transparency in 2007. The principles explicitly state that 
information about member organisations‟ finances, revenue sources and amounts, in sum 
and as a percentage of the organisational budget, shall be made public at least six months 
after review by the organisations‟ General Assemblies. The names of public and private 
funders are to be also be disclosed, as well as the purpose of the contribution. According to 
these principles, compliance will be monitored by the European Commission at least every 
two years and outstanding information will be noted in the Forum.xvii However, some EMA-
eligible organisations surveyed in this research article also participate in the EU HPF. 
Therefore, it is reasonable to assume that the EU HPF‟s financial disclosure guidelines are 
not yet instituted by all members.  
 
The Pharmaceutical Forum was a high-level political platform, administered by DG 
Enterprise and Industry from 2007 to 2008, to host discussions on EU pharmaceutical policy, 
including the issue of the provision of information to patients. The Forum did not establish 
clear financial disclosure criteria nor did it have a procedure for members to declare potential 
competing interests. Patient and consumer representatives were hand-picked by DG 
Enterprise & Industry without clear participation criteria and with no objective assessment of 
their representivity or potential conflicts of interest. xviii  
The EMA was moved under the oversight of DG SANCO in 2010 but was previously under 
the competence of DG Enterprise & Industry. Financial transparency guidelines applied to 
patient and consumer groups eligible to work with the EMA remain unchanged since their 
adoption in 2005. 
Increased transparency through research  
The performance of this project has led to greater disclosure by the eligible groups, 
particularly as a result of requests to individual organisations for financial data in the EMA 
format. In several cases, organisations updated their websites and financial records 
immediately after receiving our request. The rapid responses to requests for information 
facilitated the data collection, and contributed greatly to this study. 
The data collection process has illustrated how few data on corporate contributions are 
available. For example, one organisation‟s corporate income was estimated, through 
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methods step 1 and 2, to be between 10% and 16% of their annual income in 2006 and 
2007, respectively.5 After requesting and receiving the organisation‟s complete annual 
financial reports in methods step 3, the corporate sponsorship level was in fact between 25% 
and 56% higher than the available information originally suggested.  
Study limitations  
There are several limitations to this study. First, in the absence of sufficient financial data, 
some corporate donations had to be estimated, and so, the data may not represent the exact 
levels of sponsorship. The results in this article are based on an estimation method 
developed to yield a conservative estimate of the true value of sponsorship. As illustrated 
above, estimates based on information from organisations and company websites were 
below the actual value of contributions when compared with the financial data individual 
organisations provided on request.  
Second, this research was carried out by the HAI Europe office, which is also a consumer 
group eligible to work with the Agency and, since February 2010, an active member of the 
Patients‟ and Consumers‟ Working Party. HAI Europe‟s ongoing relationship with the Agency 
and inclusion as a research subject is clearly stated in order to make the research methods, 
results and objectivity of the analysis as transparent as possible for the reader. Opportunities 
for undue influence in this study are limited as the data retrieved are largely self-reported 
evidence, in the public domain, and verifiable by third parties. Three information sources 
were used to triangulate data collection and maximise data reliability. As with all other 
organisations, HAI‟s financial data reported in this study were retrieved from publicly 
available information on HAI‟s website.  
Conclusions  
This study indicates a low level of compliance with EMA guidelines, which were introduced in 
2005 to ensure the financial transparency of the organisations working with the Agency. 
Levels of corporate sponsorship differ greatly between those organisations that receive no 
financial support and others who rely upon it heavily. Specifically, this study has identified the 
confusion surrounding the term “financial contribution”.  
There is an absence of a uniform and detailed financial reporting system applied to civil 
society groups active in European pharmaceutical policy making. A stronger drive towards 
the harmonisation of financial disclosure criteria not only at the EMA, but also within the 
European Commission and across EU agencies is needed. A clear definition and uniform 
                                                 
5
 This estimate is based on relevant but incomplete financial information from the organisation‟s home 
website and donor company websites. 
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reporting format are essential to achieve complete disclosure and to support conflict of 
interest assessment. 
The focus of this study is the issue of corporate sponsorship in relation to patient and 
consumer organisations active at the EMA. However, these organisations represent only a 
selection of non-governmental organisations (NGOs) and other stakeholders active in the 
area of health and pharmaceutical policy in Europe. Thus, further research is called for on 
financial transparency, and the nature of corporate sponsorship and conflicts of interests of 
civil society representatives in European health policy making.  
Recommendations  
Several recommendations for concerned stakeholders arise from the conclusions of this 
study.  
Recommendations for the European Medicines Agency 
 Enforce the precise reporting format outlined in the existing financial transparency 
criteria. 
 Strengthen the financial transparency criteria by establishing a clear definition of 
“financial contributions” that includes honorariums, travel fees and other forms of 
sponsorship to support full disclosure and complete reporting. 
 Establish fixed deadlines for the submission of financial disclosure reports to the EMA 
(i.e. annually). 
 Be responsible to set up and execute monitoring and enforcement mechanisms to 
ensure that the information is publicly available, potentially on the EMA website. 
 Make participation in EMA activities conditional on the fulfilment of all criteria, with 
particular regard to financial transparency. 
 
Recommendations for patient and consumer organisations 
 Include references to the organisation‟s funding policy in financial reports, to enable 
third parties to clarify quickly and easily whether organisations accept corporate 
contributions or not, and if so for what purposes.  
 Move towards full disclosure of all financial contributions, including honorariums and 
travel fees, in order to prevent discrepancies between the organisation‟s annual reports 
and the sponsor‟s declarations. 
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 Post regular and easily accessible financial reports on the organisation‟s website and 
other relevant registers, such as the European Commission‟s lobby register, 
particularly for groups involved as a stakeholder in European health platforms. 
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